Literature DB >> 27181389

Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.

Donghai Dai1, Kristina W Thiel1, Erin A Salinas1, Michael J Goodheart2, Kimberly K Leslie2, Jesus Gonzalez Bosquet3.   

Abstract

OBJECTIVE: Patients with endometrioid endometrial cancer are stratified as high risk and low risk for extrauterine disease by surgical staging. Since patients with low-grade, minimally invasive disease do not benefit from comprehensive staging, pre-surgery stratification into a risk category may prevent unnecessary surgical staging in low risk patients. Our objective was to develop a predictive model to identify risk levels using somatic mutations that could be used preoperatively.
METHODS: We classified endometrioid endometrial cancer patients in The Cancer Genome Atlas (TCGA) dataset into high risk and low risk categories: high risk patients presented with stage II, III or IV disease or stage I with high-intermediate risk features, whereas low risk patients consisted of the remaining stage I patients with either no myometrial invasion or low-intermediate risk features. Three strategies were used to build the prediction model: 1) mutational status for each gene; 2) number of somatic mutations for each gene; and 3) variant allele frequencies for each somatic mutation for each gene.
RESULTS: Each prediction strategy had a good performance, with an area under the curve (or AUC) between 61% and 80%. Analysis of variant allele frequency produced a superior prediction model for risk levels of endometrial cancer as compared to the other two strategies, with an AUC=91%. Lasso and Ridge methods identified 53 mutations that together had the highest predictability for high risk endometrioid endometrial cancer.
CONCLUSIONS: This prediction model will assist future retrospective and prospective studies to categorize endometrial cancer patients into high risk and low risk in the preoperative setting.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; Individualized treatment; Prediction model; Risk levels; Somatic mutations

Mesh:

Year:  2016        PMID: 27181389      PMCID: PMC5257080          DOI: 10.1016/j.ygyno.2016.05.012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  38 in total

1.  FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  2014-02-22       Impact factor: 3.561

2.  Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma.

Authors:  Patricia A Convery; Leigh A Cantrell; Nicola Di Santo; Gloria Broadwater; Susan C Modesitt; Angeles Alvarez Secord; Laura J Havrilesky
Journal:  Gynecol Oncol       Date:  2011-07-13       Impact factor: 5.482

3.  Assessing the performance of prediction models: a framework for traditional and novel measures.

Authors:  Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

4.  Systemic lymphadenectomy cannot be recommended for low-risk corpus cancer.

Authors:  Takao Hidaka; Akitoshi Nakashima; Tomoko Shima; Toru Hasegawa; Shigeru Saito
Journal:  Obstet Gynecol Int       Date:  2010-02-04

5.  Clonal analysis of human colorectal tumors.

Authors:  E R Fearon; S R Hamilton; B Vogelstein
Journal:  Science       Date:  1987-10-09       Impact factor: 47.728

6.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Stefano Basile; Francesco Maneschi; Andrea Alberto Lissoni; Mauro Signorelli; Giovanni Scambia; Roberto Angioli; Saverio Tateo; Giorgia Mangili; Dionyssios Katsaros; Gaetano Garozzo; Elio Campagnutta; Nicoletta Donadello; Stefano Greggi; Mauro Melpignano; Francesco Raspagliesi; Nicola Ragni; Gennaro Cormio; Roberto Grassi; Massimo Franchi; Diana Giannarelli; Roldano Fossati; Valter Torri; Mariangela Amoroso; Clara Crocè; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2008-11-25       Impact factor: 13.506

7.  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.

Authors:  Andrea Mariani; Sean C Dowdy; William A Cliby; Bobbie S Gostout; Monica B Jones; Timothy O Wilson; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2008-03-04       Impact factor: 5.482

8.  CMA: a comprehensive Bioconductor package for supervised classification with high dimensional data.

Authors:  M Slawski; M Daumer; A-L Boulesteix
Journal:  BMC Bioinformatics       Date:  2008-10-16       Impact factor: 3.169

9.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.

Authors:  H Kitchener; A M C Swart; Q Qian; C Amos; M K B Parmar
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

10.  Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

Authors:  Muhammed Murtaza; Sarah-Jane Dawson; Katherine Pogrebniak; Oscar M Rueda; Elena Provenzano; John Grant; Suet-Feung Chin; Dana W Y Tsui; Francesco Marass; Davina Gale; H Raza Ali; Pankti Shah; Tania Contente-Cuomo; Hossein Farahani; Karey Shumansky; Zoya Kingsbury; Sean Humphray; David Bentley; Sohrab P Shah; Matthew Wallis; Nitzan Rosenfeld; Carlos Caldas
Journal:  Nat Commun       Date:  2015-11-04       Impact factor: 14.919

View more
  2 in total

1.  A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables.

Authors:  Erin A Salinas; Marina D Miller; Andreea M Newtson; Deepti Sharma; Megan E McDonald; Matthew E Keeney; Brian J Smith; David P Bender; Michael J Goodheart; Kristina W Thiel; Eric J Devor; Kimberly K Leslie; Jesus Gonzalez Bosquet
Journal:  Int J Mol Sci       Date:  2019-03-09       Impact factor: 5.923

2.  Creation and validation of models to predict response to primary treatment in serous ovarian cancer.

Authors:  Jesus Gonzalez Bosquet; Eric J Devor; Andreea M Newtson; Brian J Smith; David P Bender; Michael J Goodheart; Megan E McDonald; Terry A Braun; Kristina W Thiel; Kimberly K Leslie
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.